๐๐ง๐ญ๐ซ๐จ๐๐ฎ๐๐ข๐ง๐ ย ๐๐ก๐๐ซ๐ฆ๐๐ซ๐จ๐งโ๐ฌย ๐๐๐ ๐๐๐๐ข๐ง๐๐ซ ๐จ๐งย ๐๐๐ ๐๐๐ฏ๐๐ฅ๐จ๐ฉ๐ฆ๐๐ง๐ญ
๐
๐ซ๐จ๐ฆ ๐๐๐ง๐๐ข๐๐๐ญ๐ ๐ญ๐จ ๐๐ฅ๐ข๐ง๐ข๐: ๐๐๐ฏ๐ข๐ ๐๐ญ๐ข๐ง๐ ๐๐๐ ๐๐๐ฏ๐๐ฅ๐จ๐ฉ๐ฆ๐๐ง๐ญ ๐๐ฉ๐๐๐ ๐๐จ๐ฐ๐๐ซ๐ ๐
๐๐ ๐๐ฅ๐ข๐ง๐ข๐๐๐ฅ ๐๐ญ๐ฎ๐๐ข๐๐ฌ
๐ ๐๐๐ฒ ๐๐๐๐ | ๐ ๐๐ฆ ๐๐ / ๐๐ ๐๐ฆ ๐๐ / ๐ ๐ฉ๐ฆ ๐๐๐
As emerging drug candidates become increasingly complex and pressure for rapid clinical entry intensifies, early planning of quantity, quality, and supply of API is more important than ever. Theย webinarย will outline best practices forย establishingย a robust supply route,ย optimizingย synthetic processes, and selectingย appropriate regulatoryย starting materials to enable efficient GMP production.
๐
๐๐๐ญ๐ฎ๐ซ๐๐ ๐๐ฉ๐๐๐ค๐๐ซ๐ฌ:
– Aaron Dumas โย Senior Director, Process Chemistry at Pharmaron
– Brett Cooper โย Senior Director, Analytical and Material Science at Pharmaron
๐๐จ๐๐๐ซ๐๐ญ๐จ๐ซ:
– Peter Shapland โย Senior Director, Drug Substance Commercialisation at Pharmaron
๐๐๐๐ฎ๐ซ๐ ๐ฒ๐จ๐ฎ๐ซ ๐ฌ๐ฉ๐จ๐ญ ๐ญ๐จ๐๐๐ฒ and be part of the conversation shaping the future ofย API development: